Read clinical review Comparing Wegovy (semaglutide 2.4 mg) and liraglutide for weight management, including efficacy data from STEP-1 and SCALE, dosing differences, and a clinical switching protocol
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease
The American Heart Association's Heart Disease and Stroke Statistics report has documented significant racial disparities in comorbidity management outcomes and healthcare delivery [116]
Flavor matters more than most people expect, since you are far more likely to stay consistently hydrated if you enjoy drinking it